Autopsy report · NCT04488575

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

“Insufficient study defined patient population”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 9 months before it stopped.
• 16 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Evelo Biosciences, Inc.

Sponsor type

Industry

Conditions

Covid19

Interventions

EDP1815; Placebo

Participants

16

Sites

4

Countries

Turkey (Türkiye), United States

Trials that died the same way

• POLA+BR for Relapsed or Refractory DLBCL
  “Lack of sufficient patient population” (79% match in meaning)
• Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion
  “Study is being closed due to insufficient patient population for enrollment.” (78% match in meaning)
• Efficacy of EndoClot™ Spraying After Endoscopic Resection of Large Colorectal Polyps
  “insufficient recruitment of study patients” (76% match in meaning)
• Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
  “Lack of patient population” (75% match in meaning)
• Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease
  “difficulties recruiting this population for study population” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.